Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Evolus Inc (NQ: EOLS )

8.780 -0.200 (-2.23%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 26, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 312,477
Open 9.060
Bid (Size) 8.750 (1)
Ask (Size) 8.780 (1)
Prev. Close 8.980
Today's Range 8.740 - 9.140
52wk Range 6.510 - 14.30
Shares Outstanding 54,576,156
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Expert Ratings for Evolus
 
Via Benzinga
This Analyst Likes Evolus As 'Top Play In Aesthetics'
Evolus Inc (NASDAQ: EOLS) will be the exclusive U.S. 
Via Benzinga

Performance

YTD
+12.13%
+12.13%
1 Month
+0.92%
+0.92%
3 Month
-1.13%
-1.13%
6 Month
+23.84%
+23.84%
1 Year
-31.94%
-31.94%

More News

Read More
Expert Ratings for Evolus
Via Benzinga
Evolus: Q1 Earnings Insights
Via Benzinga
Evolus Reports First Quarter 2023 Results and Provides Business Update
From Evolus
Via Business Wire
Evolus Announces Expansion into U.S. Dermal Filler Market with Evolysse™, a First-Generation Cold Technology HA by Symatese
From Evolus, Inc.
Via Business Wire
Evolus Earnings Preview
Via Benzinga
Analyst Expectations for Evolus's Future
Via Benzinga
Preview: Evolus's Earnings
Via Benzinga
Evolus Says 'Extra Strength' Jeuveau Shows A Durable Effect In Frown Lines
Via Benzinga
Evolus to Report First Quarter 2023 Results and Provide Business Update
From Evolus, Inc.
Via Business Wire
Evolus Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update
From Evolus
Via Business Wire
Evolus to Participate in the Barclays Global Healthcare Conference
From Evolus
Via Business Wire
Evolus Initiates Nuceiva® Launch in Germany and Austria
From Evolus, Inc.
Via Business Wire
Earnings Scheduled For March 8, 2023
Via Benzinga
Evolus to Report Fourth Quarter and Year End 2022 Results and Provide Business Update
From Evolus
Via Business Wire
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Evolus Not Affected by Recent Korean Court Ruling
From Evolus
Via Business Wire
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Evolus to Participate in the SVB Securities Global Biopharma Conference
From Evolus
Via Business Wire
"Extra-Strength" Formulation of Jeuveau® Demonstrates Effects Lasting 26 Weeks in Interim Phase II Data Results, Representing Prolonged 6-Month Performance
From Evolus
Via Business Wire
Evolus Receives Regulatory Approval for Nuceiva® in Australia
From Evolus
Via Business Wire
Evolus to Present Phase 2 Interim Data from Jeuveau® “Extra-Strength” Dose for Extended Duration Study at 2023 IMCAS World Congress
From Evolus
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.